Tolerability and safety of the intravenous immunoglobulin Octagam®: A 10-year prospective observation study

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 9, 2007, Pages 1038-1047

  Debes, Anette ^a   Bauer, Maria ^a   Kremer, Sybille ^a  

^a Octapharma GmbH   (Germany)

Author keywords

Adverse drug reaction; Autoimmune disease; Immunodeficiency; IVIg; Prospective observation cohort study; Safety; Tolerability

Indexed keywords

IMMUNOGLOBULIN G;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; BACKACHE; CHILD; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COHORT ANALYSIS; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; COUGHING; CYANOSIS; DERMATITIS; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FLUSHING; GUILLAIN BARRE SYNDROME; HEART PALPITATION; HEMIPLEGIA; HOT FLUSH; HUMAN; HYPERIMMUNOGLOBULINEMIA; HYPERTENSION; HYPOGAMMAGLOBULINEMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; INFANT; INJECTION SITE REACTION; ISCHEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NAUSEA; NERVOUSNESS; NEWBORN; OBSERVATIONAL STUDY; PALLOR; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RECOMMENDED DRUG DOSE; RIGOR; SIDE EFFECT; SOMNOLENCE; SWEATING; TACHYCARDIA; THORAX PAIN; UNSPECIFIED SIDE EFFECT; URTICARIA; VISUAL DISORDER; VOMITING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548708026     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1449     Document Type: Article

References (38)

1. Durandy A, Wahn V, Petteway S, et al. Immunoglobulin replacement therapy in primaiy antibody deficiency diseases-maximizing success. Int Arch Allergy Immunol 2005; 136: 217-229.
2. Buckley RH, Schiff RI. Drug therapy: the use of intravenous immune globulin in immunodeficiency diseases. New Engl J Med 1991; 325: 110-117.
3. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988; 319: 902-907.
4. Chapel HM, Lee M, Hargreaves R, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994; 343: 1059-1063.
5. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705-712.
6. Sullivan KM. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Clin Exp Immunol 1996; 104 (Suppl. 1): 43-48.
7. Kiehl MG, Muller C. The optimum use of intravenous immunoglobulin for prophylaxis of opportunistic infection in HIV-infected adults. Biodrugs 1998; 10: 265-273.
8. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group 2. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 325: 73-80.
9. Imbach P, Morell A. Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg). Int Rev Immunol 1989; 5: 181-188.
10. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004; 102: 177-193.
11. Hahn AF. Intravenous immunoglobulin treatment in peripheral nerve disorders - indications, mechanisms of action and side-effects. Curr Opin Neurol 2000; 13: 575-582.
12. Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology 1996; 46: 100-103.
13. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997; 41: 789-796.
14. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119(Pt 4): 1067-1077.
15. Mendell JR. Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445-449.
16. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 1992; 326: 1123-1129.
17. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349: 589-593.
18. Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004; 61: 1515-1520.
19. Sorensen PS, Wanscher B, Schreiber K, et al. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. Mult Scler 1997; 3: 145-148.
20. Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neuro 2002; 9: 557-563.
21. Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy 2005; 25: 78S-84S.
22. Volume 9-Pharmacovigilance Medicinal Products for Human Use and Veterinary Medicinal Products. Rules governing Medicinal Products in the European Union 2004; 1-385.
23. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999; 21: 171-185.
24. Brenner B. Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin. Clin Exp Rheumatol 1996; 14 (Suppl. 15): S115-S119.
25. Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol 2006; 19: 3-25.
26. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6: 535-542.
27. Ochs HD, Pinciaro PJ. The Octagam Study Group. Octagam® 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004; 24: 309-314.
28. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003; 133: 247-251.
29. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20: 94-100.
30. Tcheurekdjian H, Martin J, Kobayashi R, et al. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states. Allergy Asthma Proc 2006; 27: 532-536.
31. Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child 2006; 91: 651-654.
32. Hopkins S, Jolles S. Drug-induced aseptic meningitis. Expert Opin Drug Saf 2005; 4: 285-297.
33. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259-262.
34. Wilhelm G, Schulze H. Massiver Hirninfarkt unter intravenöser Immunglobulintherapie. Arzneimitteltherapie 1997; 15 Jahrgang: 63-64.
35. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol 2004; 83: 661-665.
36. Vecchietti G, Kerl K, Prins C, et al. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol 2006; 142: 213-217.
37. Maetzke J, Sperfeld AD, Scharffetter-Kochanek K, et al. Vesicular and bullous eczema in response to intravenous immunoglobulins (IVIG). Allergy 2006; 61: 145-146.
38. Hasford J, Goettler M, Munter KH, et al. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002; 55: 945-950.